At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the long-term. One way of addressing these unmet needs could be brolucizumab, the first humanized single-chain antibody fragment to be developed in medicine. Due to the small molecular size of brolucizumab, it can achieve enhanced tissue penetration and remain in the target for an extended period. Dr Dugel gives us a run-down of the HAWK and HARRIER study results and looks to the future of anti-VEGF therapies.
1. What are the major unmet needs in the treatment of neovascular age-related macular degeneration (nAMD)? (0:08)
2. How does brolucizumab differ from other anti-vascular endothelial growth factor (VEGF) treatment options in nAMD? (0:44)
3. What were the major findings of the HAWK and HARRIER studies comparing brolucizumab with aflibercept in patients with nAMD? (1:31)
4. Could you tell us about the recent analysis of the HAWK and HARRIER data investigating the reliability of response to an initial 12-week treatment interval in predicting long-term response to this dosing regimen? (2:26)
5. What are the next steps in the clinical development of brolucizumab for nAMD and what will this mean in terms of your clinical practice? (3:29)
Scientific advisory board: Alcon Surgical (RACII), Genentech, MacuSight, Novartis, NeoVista, ArticDX, Alcon Pharmaceutical, AMO, Thrombogenics, Santen, Ophthotech, Lux BioScience, Digisight, Roche, Acucela, Stealth Biotherapeutics, Lutronic, Avalanche, TrueVision, Alimera Sciences, Orbis International, Annidis, Neurotech, Aerpio, DOSE Medical, Omeros, Shire Human Genetics, Opthea, Graybug Vision, CDR-Life Inc., Clearside Biomedical.
Consultant: Bausch + Lomb Pharma, Genentech, Alcon Surgical, Alcon Pharmaceutical, NeoVista, MacuSight, ArticDX, ORA, Novartis, Allergan, Regeneron, Santen, Inc., QLT, Inc., Abbott/AMO, Thrombogenics, Ophthotech, Lux BioScience, DigiSight, Roche, TopCon, Acucela, Pentavision, ORA, Stealth Biotherapeutics, Annidis, Clearside Biomedical, Optovue, Neurotech, Lutronic, Alimera Sciences, DOSE Medical, Aerpio, Omeros, Shire Human Genetics, Ophthea, Spark Therapeutics, Graybug Vision, Zeiss Group, Irenix, ByeOnics, PanOptica, Chengdu Kanghong Biotechnology, SciFluor Life Sciences, Boehringer Ingelheim, Kodiak Sciences, Oculis SA, pSivida Corporation, Amgen, Aerie Pharmaceutical, Pieris Pharmaceutical, Gemini Pharmaceutical, Ionis, RegenexBio, Reneuron, Abfero.
Minor stockholder: Alimera, Aerpio, Annidis, ArctixDx, Digisight, Irenix, Ophthotech, Clearside Biomedical, PanOptica, True Vision.
Filmed at the European Society of Retina Specialists (EURETINA) 2018 Congress, Vienna, Austria, 20–23 September 2018.
Share this Video
Related Videos In Retina/Vitreous
David Boyer, ARVO 2023: Phase IIb RESTORE trial: MCO-010 optogenetic therapy for vision restoration in patients with retinitis pigmentosa
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]
David Boyer, ARVO 2023: Retinitis Pigmentosa and the unmet needs in its treatment
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa […]
Carl Regillo, Hawaiian Eye and Retina 2023: New and emerging treatments for neovascular age-related macular degeneration
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!